Clinical monitoring refers to the systematic observation and oversight of either a patient’s health status or the conduct of a clinical trial. The term spans two distinct contexts: in hospitals and clinics, it means tracking vital signs like heart rate, blood pressure, and oxygen levels; in clinical research, it means verifying that a trial is run safely, ethically, and according to its protocol. Both share the same core goal of protecting people, but they work very differently in practice.
Patient Monitoring in Healthcare Settings
In a hospital or clinic, clinical monitoring means continuously or periodically measuring a patient’s physiological functions. The most common parameters tracked are heart rate, blood pressure, oxygen saturation, breathing rate, and body temperature. Bedside monitors display this information in real time, alerting staff when a reading falls outside a safe range. This type of monitoring is routine in intensive care units, during surgery, and after major procedures.
Beyond the hospital, wearable devices have expanded clinical monitoring into everyday life. Smartwatches and wrist-worn bands are the most common form, making up about 63% of devices studied in wearable health research. These devices can track movement and activity, step count, heart rate, ECG rhythms, sleep quality, skin temperature, and blood oxygen levels. Products range from consumer devices like the Apple Watch and Fitbit to specialized medical tools like the ZIO XT patch for heart rhythm monitoring, the LifeVest external defibrillator, and even sensor-embedded diabetic socks that detect dangerous pressure points on the feet.
The U.S. FDA finalized guidance in December 2023 on using digital health technologies to collect data remotely from participants in clinical settings. The agency noted that these tools can improve efficiency for both healthcare providers and patients while making it easier for more people to participate in research or receive ongoing care from home.
Clinical Trial Monitoring
In the research world, clinical monitoring has a specific regulatory definition. The International Council for Harmonisation (ICH) defines it as overseeing the progress of a clinical trial to ensure it is “conducted, recorded, and reported in accordance with the protocol, standard operating procedures, good clinical practice, and applicable regulatory requirements.” The aim is to protect participants’ rights, safety, and well-being while ensuring the trial’s results are reliable.
This work is carried out primarily by Clinical Research Associates, sometimes called monitors or CRAs. They serve as the link between the company sponsoring the trial and the hospitals or clinics running it. Their job touches every phase of a study, from setup through completion.
What a Monitor Actually Does
A CRA’s responsibilities shift depending on the stage of the trial. During a site initiation visit, the monitor reviews the study protocol with the research team, trains investigators and staff on the study’s requirements, and sets up systems for data collection, reporting, and documenting side effects.
Once the trial is enrolling patients, CRAs make regular on-site visits to check that the site is following the protocol and regulatory rules. They review informed consent documents to make sure every participant properly agreed to join, verify that enrolled patients actually met the eligibility criteria, examine data collection for accuracy, and assess participant safety by reviewing adverse event reports. They also confirm that the site is keeping adequate records.
When a trial wraps up, the CRA conducts a close-out visit. This involves confirming all study data has been collected and documented, resolving any remaining data questions or discrepancies, verifying that regulatory requirements are met, and ensuring the site returns all study materials, including unused drugs, equipment, and documentation.
Source Data Verification
One of the most time-consuming parts of traditional monitoring is source data verification, or SDV. This means comparing the data entered into the study’s electronic case report forms against the original records in a patient’s hospital chart, lab printouts, or imaging reports. Historically, monitors checked 100% of data points, a practice that required dedicated staff combing through hospital notes line by line.
That approach is expensive and, as it turns out, not especially effective. A landmark 2014 analysis concluded that 100% SDV catches only a small number of transcription errors and has limited impact on overall data quality compared with more strategic approaches. Despite that evidence, and encouragement from regulators to move away from it, 100% SDV remains deeply ingrained in the industry.
Risk-Based Monitoring
The shift away from blanket verification led to risk-based monitoring, a framework that focuses resources on the data and processes most likely to affect participant safety or study results. Instead of checking everything equally, sponsors conduct risk assessments at the start of a trial and throughout its duration, then direct monitoring efforts toward the factors that truly matter.
The framework relies on several key tools. Centralized monitoring pulls together data from multiple sources, including electronic data collection systems, patient-reported outcomes, digital diaries, lab tests, and wearable devices. Reviewing this data from a central location allows teams to spot protocol deviations, gaps in adverse event reporting, and safety concerns in near real time, without anyone physically visiting a site. Key risk indicators and quality tolerance limits flag anomalies at specific sites, triggering targeted on-site visits only when something looks off.
This combination means CRAs can spend their on-site time on tasks that genuinely require a physical presence, like confirming participant eligibility, assessing whether the site is following the protocol, and reviewing processes that can’t be evaluated from a database alone. A Japanese study found that sites using partial SDV spent 30% less monitoring time compared with sites doing full verification, with no meaningful loss in data quality.
Before the COVID-19 pandemic, adoption of these approaches was still low. Only about 25% of trials used off-site remote monitoring, 20% used reduced SDV, and just 16% employed centralized monitoring. The pandemic forced rapid adoption of remote methods, and the industry has continued moving in that direction since.
Standards for Drugs and Medical Devices
Clinical monitoring requirements are governed by overlapping international standards. For drug trials, ICH E6 (Good Clinical Practice) is the primary framework. For medical device investigations, ISO 14155 fills a parallel role. Both standards allow flexibility in how trials are monitored, advising sponsors to consider the trial’s objectives, design, complexity, size, and endpoints when deciding how much monitoring a study needs. The ISO standard specifically requires sponsors to use that assessment to develop a formal monitoring plan.
Both frameworks also accommodate modern data collection methods. Original observations can be entered directly into electronic case report forms or transmitted from various locations, devices, or instruments. The ISO standard requires the clinical investigation plan to specify which data can be recorded directly in CRFs, providing a clear audit trail regardless of where the data originates.
Data Privacy in Clinical Monitoring
Whether monitoring happens at a bedside or across a network of trial sites, patient data must be protected. In the United States, HIPAA requires that all electronic protected health information be encrypted during transfer. Any vendor handling this data, whether a remote monitoring platform, a wearable device company, or a trial data management system, must sign a business associate agreement with the covered entity. That agreement spells out the methods used to protect the data and includes provisions for regular security audits. These requirements apply equally to data flowing from a hospital monitor to a nurse’s station and to trial data transmitted from a clinic to a sponsor’s central database.